Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (Nasdaq: RVMD) reported Q2 2022 financial results and significant progress in its clinical development pipeline targeting RAS-addicted cancers. The company commenced patient dosing in its Phase 1/1b trials for RMC-6236 and RMC-6291, advancing its RAS(ON) Inhibitor portfolio. They raised $265 million through public equity financing to support these developments. Notably, total revenue increased to $9.1 million, while net loss widened to $61.2 million. The company projected a net loss of $260 to $280 million for 2022, but affirmed sufficient funds to operate through 2024.
Revolution Medicines (Nasdaq: RVMD) will announce its Q2 2022 financial results on August 9, 2022, post-market close. A conference call led by the senior management team is scheduled for 4:30 p.m. ET to discuss the results and corporate progress. The company focuses on RAS-addicted cancers with a diverse pipeline of RAS(ON) Inhibitors, including RMC-6236 and RMC-6291, among others. The live conference can be accessed via a dedicated webcast.
Revolution Medicines has successfully completed a public offering of 13,225,000 shares of common stock at $20.00 per share, raising gross proceeds of $264.5 million. This includes the full exercise of an underwriters' option for an additional 1,725,000 shares. The offering, which is targeted at advancing the company’s oncology pipeline, was managed by J.P. Morgan, Cowen, and Guggenheim Securities. This offering follows a shelf registration statement filed with the SEC in March 2021.
Revolution Medicines, Inc. (Nasdaq: RVMD) has announced an underwritten public offering of 11,500,000 shares of common stock priced at $20.00 per share, aiming for gross proceeds of $230 million. The offering is set to close on July 22, 2022, pending customary conditions. Additionally, underwriters have a 30-day option to buy 1,725,000 more shares. J.P. Morgan, Cowen, and Guggenheim Securities are the joint book-running managers. This move is designed to further support the development of targeted therapies for RAS-addicted cancers.
Revolution Medicines (NASDAQ: RVMD) has announced a public offering of up to $200 million of common stock, with a potential additional $30 million available through underwriters. The offering is subject to market conditions, and completion is not guaranteed. The company focuses on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes RAS(ON) Inhibitors and RAS Companion Inhibitors. The offering aims to fund further development of these therapies.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced the appointment of Lorence Kim, M.D. to its board of directors on July 13, 2022. Dr. Kim, formerly CFO at Moderna, brings vital operational and financial expertise crucial for the company’s development pipeline of targeted therapies for RAS-addicted cancers. He replaces Neil Exter, enhancing the board as clinical trials for RMC-6236 and RMC-6291 progress. The company continues to make strides in evaluating drug combinations, particularly RMC-4630 with sotorasib, showing promising results that may advance cancer treatment.
Revolution Medicines (Nasdaq: RVMD) announced the initiation of patient dosing in its Phase 1/1b clinical trial of RMC-6236, a novel oral RAS(ON) Inhibitor targeting cancers driven by KRAS mutations. This trial represents a significant milestone as RMC-6236 is the first oral, direct RAS inhibitor assessed against tumors with the KRASG12D variant. The study aims to evaluate safety, tolerability, and determine the recommended Phase 2 dose. Additionally, Sushil Patel, Ph.D., has been elected to the board, bringing extensive oncology commercialization experience.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on therapies for RAS-addicted cancers, will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference from June 13-16, 2022. CEO Mark A. Goldsmith will host a live fireside chat on June 15, 2022, at 1:20 p.m. Pacific Time. Investors can access the live webcast at here, with an archived replay available for 14 days post-event.
Revolution Medicines, a clinical-stage oncology company, reported its Q1 2022 financial results, revealing a net loss of $57.6 million, up from $37.2 million in Q1 2021. Total revenue decreased to $7.6 million from $10.2 million year-over-year, mainly due to lower reimbursed development costs with Sanofi. However, the company is advancing its RAS(ON) Inhibitor pipeline, with RMC-6236 and RMC-6291 set to enter clinical trials this year. The company maintains a strong cash position of $518.8 million and expects a full-year net loss of $260 million to $290 million for 2022.
Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the upcoming release of its financial results for Q1 2022 on May 9, 2022, after market close. The senior management team will conduct a conference call and webcast at 4:30 PM ET to discuss these results and update investors on corporate progress. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, including a diverse pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors. More details on the call can be found on their investor relations website.